IBD

Nucleai and GoPath Diagnostics Announce Strategic Collaboration to Provide Integrated AI-powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications

Retrieved on: 
Monday, April 8, 2024
Other Health, Software, Research, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, College, GCP, LMS, Algorithm, Prostate cancer, Case management, Good clinical laboratory practice, Partnership, LIMS, CLEP, Biomarker, GCLP, AI, CAP, Good clinical practice, IBD, Medicine, Workflow, CLIA, Pathology, Inflammatory bowel disease, Medical director, Medical device

Nucleai , a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, today announced a strategic collaboration with GoPath Diagnostics , a leading full-service digital pathology and molecular diagnostics laboratory.

Key Points: 
  • Nucleai , a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, today announced a strategic collaboration with GoPath Diagnostics , a leading full-service digital pathology and molecular diagnostics laboratory.
  • This partnership unites Nucleai and GoPath's complementary skills to expedite the development of new AI-powered clinical research and diagnostics.
  • The integrated solutions will be deployed within a centralized environment that meets the standards of the College of American Pathologists (CAP), Clinical Laboratory Improvement Amendments (CLIA), Clinical Laboratory Evaluation Program (CLEP), Good Clinical Practice (GCP), and Good Clinical Laboratory Practice (GCLP).
  • Jim Lu, M.D., CEO and Medical Director for GoPath Diagnostics, said: “Our collaboration with Nucleai transforms our capabilities, enabling GoPath to deliver a seamlessly integrated lab workflow.

Clinical Data Supports Novel Continuous Calprotectin Monitoring Wearable for IBD Management by EnLiSense

Retrieved on: 
Monday, April 8, 2024
Technology, Medical Devices, Health Technology, Nanotechnology, Other Health, Biotechnology, Hardware, Managed Care, Health, Data Management, Moses Austin, Conditional sentence, University, Professor, IL-6, Perspiration, Patient, Inflammation, Biomarker, Research, AI, Doctor of Philosophy, Senior, IBD, Translation, Management, C-reactive protein, Inflammatory bowel disease, Inflammatory Bowel Diseases, Trial of the century, CRP, Pharmaceutical industry

The study showcases the IBD Aware device's ability to non-invasively monitor calprotectin levels in both active and remission phases of IBD.

Key Points: 
  • The study showcases the IBD Aware device's ability to non-invasively monitor calprotectin levels in both active and remission phases of IBD.
  • These results not only affirm the accuracy of the IBD Aware device, but demonstrate its utility in the shifting paradigm of proactive IBD management that emphasizes continuous, data-driven decision-making.
  • “The IBD Aware device exemplifies our dedication to empowering healthcare professionals and enhancing patient outcomes through remote and continuous monitoring."
  • EnLiSense is pioneering work to build a future where proactive, personalized, and precision remote patient monitoring becomes the standard in chronic disease management.

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

Retrieved on: 
Monday, March 25, 2024
AbbVie, Ulcerative colitis, Patient, Inflammation, ABBV, Acquisition, IBD, MOA, Therapy, NLRX1, Calendar, Pharmaceutical industry

NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.

Key Points: 
  • NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.
  • Landos’ lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates epithelial repair.
  • “NX-13 and its bimodal MOA have the potential to provide a novel approach to the treatment of ulcerative colitis and Crohn’s disease.
  • The proposed transaction is expected to close in the second calendar quarter of 2024, subject to customary closing conditions, including approval by Landos’ stockholders.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMLX

Retrieved on: 
Saturday, March 23, 2024
Prior, Apoptosis, ALS, District court, Patient, AMX0035, Amyotrophy, Ext, LLP, Prescription, IBD, Complaint, Pomerantz, Action Replay, Food, Court, Evercore, Person, Pharmaceutical industry

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.

Key Points: 
  • NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 22, 2024
Apoptosis, Patient, AMX0035, Science, New York Community Bank, NYCB, P.C, Initiative, ACL, Scientific misconduct, IBD, Confidentiality, Safety, Injury, Data management, Food, Signature, Cassava Sciences, ALS, Alzheimer's disease, Defendant, Food and Drug Administration, Journal, Amyotrophy, News, Prescription, Amylyx Pharmaceuticals, Dentist, FDA, City University, Biomarker, Dermatology, Complaint, Investor's Business Daily, Neurobiology of Aging, Cognition, Assumption, Category, BBC World Service, Evercore, Cassava, Pharmaceutical industry

The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.

Key Points: 
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • However, in response, Cassava denied the allegations in the Citizen Petition and instead touted the effectiveness of simufilam and the efficacy of the Company's research programs.
  • On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.
  • For more information on the InMode class action go to: https://bespc.com/cases/INMD

Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease

Retrieved on: 
Thursday, March 21, 2024
Ulcerative colitis, GPR35, Partnership, GSK, Research, Health care, Irritable bowel syndrome, Visceral pain, IBD, Therapy, Safety, Inflammatory Bowel Diseases, Pharmaceutical industry

HTL0027477 was designed by Sosei Heptares using its proprietary structure-based drug design (SBDD) platform and licensed to GSK in 2020.

Key Points: 
  • HTL0027477 was designed by Sosei Heptares using its proprietary structure-based drug design (SBDD) platform and licensed to GSK in 2020.
  • Sosei Heptares regained full ownership of the HTL0027477 program including associated intellectual property licensed by Sosei Heptares to GSK, and preclinical data generated under the partnership for no upfront payment.
  • Sosei Heptares expects to determine the optimal strategy for further clinical development of the program, which could include in-house development and re-partnering.
  • This presents a clear opportunity for Sosei Heptares to further advance this program while determining the optimal path forward for further development and commercialization.”

Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease

Retrieved on: 
Thursday, March 21, 2024
EP4, Inflammation, Biomarker, IBD, Inflammatory bowel disease, Therapy, Safety, Pharmacokinetics, Pharmaceutical industry

This approach is widely recognized to promote deeper remission and offer better long-term clinical outcomes1,2.

Key Points: 
  • This approach is widely recognized to promote deeper remission and offer better long-term clinical outcomes1,2.
  • HTL’744 aims to address the significant unmet need of people with IBD that do not achieve satisfactory disease control.
  • The trial will be conducted in the UK and initial data read-outs are anticipated from 2025.
  • EP4 agonists are a recognized and exciting class of drugs with a dual mechanism of action that can resolve inflammation and promote mucosal healing.

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

Retrieved on: 
Tuesday, March 19, 2024
Patient, LLP, Prescription, IBD, Investor's Business Daily, Amylyx Pharmaceuticals, Advertising, Court, BBC World Service, Evercore, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Amylyx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, March 18, 2024
Apoptosis, Patient, AMX0035, Science, New York Community Bank, NYCB, P.C, Initiative, ACL, Scientific misconduct, IBD, Confidentiality, Safety, Injury, Data management, Food, Signature, Cassava Sciences, ALS, Alzheimer's disease, Defendant, Food and Drug Administration, Journal, Amyotrophy, News, Prescription, Amylyx Pharmaceuticals, Dentist, FDA, City University, Biomarker, Dermatology, Complaint, Investor's Business Daily, Neurobiology of Aging, Cognition, Assumption, Category, BBC World Service, Evercore, Cassava, Pharmaceutical industry

The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.

Key Points: 
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • However, in response, Cassava denied the allegations in the Citizen Petition and instead touted the effectiveness of simufilam and the efficacy of the Company's research programs.
  • On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.
  • For more information on the InMode class action go to: https://bespc.com/cases/INMD

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMLX

Retrieved on: 
Friday, March 15, 2024
Prior, Apoptosis, ALS, District court, Patient, AMX0035, Amyotrophy, Ext, LLP, Prescription, IBD, Complaint, Pomerantz, Action Replay, Food, Court, Evercore, Person, Pharmaceutical industry

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.

Key Points: 
  • NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.